{"result": {"id": "chatcmpl-979", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "Anti-angiogenesis inhibitors have shown a clinical benefit in patients with PD-L1 expression ≥50%, although the magnitude of this benefit is currently limited.  This benefit has been observed in patients with hepatocellular carcinoma (HCC). \n", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1743240786, "model": "gemma2:2b", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_ollama", "usage": {"completion_tokens": 50, "prompt_tokens": 198, "total_tokens": 248, "completion_tokens_details": null, "prompt_tokens_details": null}}, "input": {"messages": [{"content": "\nYou are a helpful assistant responsible for generating a comprehensive summary of the data provided below.\nGiven one or two entities, and a list of descriptions, all related to the same entity or group of entities.\nPlease concatenate all of these into a single, comprehensive description. Make sure to include information collected from all the descriptions.\nIf the provided descriptions are contradictory, please resolve the contradictions and provide a single, coherent summary.\nMake sure it is written in third person, and include the entity names so we have the full context.\n\n#######\n-Data-\nEntities: \"CLINICAL BENEFIT\"\nDescription List: [\"The **clinical benefit** associated with anti-angiogenesis inhibitors has been observed in patients with **PD-L1 expression ≥50%**.  While this represents a meaningful improvement, the extent of the benefit remains limited. \\n\", \"The benefit of treatment for HCC patients\"]\n#######\nOutput:\n", "role": "user"}], "parameters": {"model": "gemma2:2b", "frequency_penalty": 0.0, "max_tokens": 500, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_summarize_2239d95aec9a53c1d69a02488743aa7f832351a838cf5dfe31bf2decc7317d86_v2"}